Natera appoints Solomon Moshkevich as new CEO
Natera announced that Solomon Moshkevich will become chief executive officer, effective November 5, 2026, succeeding Steve Chapman who will stay on as a consultant and board adviser. Moshkevich has spent 15 years at Natera, most recently as president of clinical diagnostics and the company’s first general manager of oncology. The transition was disclosed alongside the company’s third‑quarter results, which showed a 34.1% year‑over‑year revenue increase to $794 million.
Why it matters
The announcement triggered a near‑14% drop in Natera’s share price, falling to $312.98, as analysts said the unexpected leadership change created investor angst. The new CEO’s deep internal experience may provide continuity for the company’s growth in molecular diagnostics.
Key facts
- 1Solomon Moshkevich will assume the role of CEO and board member on November 5, 2026. oncodaily.com
- 2Steve Chapman will remain a consultant to Natera and serve as an adviser to the board. oncodaily.com
- 3Moshkevich has 15 years of experience at Natera, most recently as president of clinical diagnostics. finance.yahoo.com
- 4Natera reported third‑quarter revenue of $794 million, a 34.1% year‑over‑year increase. finance.yahoo.com
- 5Natera’s shares fell nearly 14% to $312.98 after the CEO announcement. finance.yahoo.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.